Alaris Ascendant
Executive Summary
Just two years ago, the merger of Ivac and Imed that created Alaris Medical seemed a last-ditch effort against entrenched industry giants Baxter and Abbott, which were offering customers an IV solutions-pump bundle that threatened Ivac's and Imed's stand-alone technology. Alaris Medical has successfully fought off its much larger competitors, winning important contract positions at many of the leading hospital purchasing groups . But the recent trend toward toward consolidation in medical supplies has company officials worried because Alaris's prospects for growth in its core business are limited.
You may also be interested in...
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.